Detecting drug communities and predicting comprehensive drug–drug interactions via balance regularized semi-nonnegative matrix factorization

BackgroundBecause drug–drug interactions (DDIs) may cause adverse drug reactions or contribute to complex-disease treatments, it is important to identify DDIs before multiple-drug medications are prescribed. As the alternative of high-cost experimental identifications, computational approaches provide a much cheaper screening for potential DDIs on a large scale manner. Nevertheless, most of them only predict whether or not one drug interacts with another, but neglect their enhancive (positive) and depressive (negative) changes of pharmacological effects. Moreover, these comprehensive DDIs do not occur at random, but exhibit a weakly balanced relationship (a structural property when considering the DDI network), which would help understand how high-order DDIs work.ResultsThis work exploits the intrinsically structural relationship to solve two tasks, including drug community detection as well as comprehensive DDI prediction in the cold-start scenario. Accordingly, we first design a balance regularized semi-nonnegative matrix factorization (BRSNMF) to partition the drugs into communities. Then, to predict enhancive and degressive DDIs in the cold-start scenario, we develop a BRSNMF-based predictive approach, which technically leverages drug-binding proteins (DBP) as features to associate new drugs (having no known DDI) with other drugs (having known DDIs). Our experiments demonstrate that BRSNMF can generate the drug communities, which exhibit more reasonable sizes, the property of weak balance as well as pharmacological significances. Moreover, they demonstrate the superiority of DBP features and the inspiring ability of the BRSNMF-based predictive approach on comprehensive DDI prediction with 94% accuracy among top-50 predicted enhancive and 86% accuracy among bottom-50 predicted degressive DDIs.ConclusionsOwing to the regularization of the weak balance property of the comprehensive DDI network into semi-nonnegative matrix factorization, our proposed BRSNMF is able to not only generate better drug communities but also provide an inspiring comprehensive DDI prediction in the cold-start scenario.

[1]  Yaoyun Zhang,et al.  Leveraging syntactic and semantic graph kernels to extract pharmacokinetic drug drug interactions from biomedical literature , 2016, BMC Systems Biology.

[2]  Xing-Ming Zhao,et al.  Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..

[3]  Zhongming Zhao,et al.  Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. , 2014, Journal of the American Medical Informatics Association : JAMIA.

[4]  Yanli Wang,et al.  Open-source chemogenomic data-driven algorithms for predicting drug-target interactions , 2019, Briefings Bioinform..

[5]  Lesly Alejandra Gonzalez Camacho,et al.  Social network data to alleviate cold-start in recommender system: A systematic review , 2018, Inf. Process. Manag..

[6]  Sebastian Polak,et al.  The Role of Interaction Model in Simulation of Drug Interactions and QT Prolongation , 2016, Current Pharmacology Reports.

[7]  N Al‐Huniti,et al.  Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling , 2016, CPT: pharmacometrics & systems pharmacology.

[8]  Jianying Hu,et al.  Label Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects , 2015, Scientific Reports.

[9]  N. Dickey,et al.  Systems analysis of adverse drug events. , 1996, JAMA.

[10]  Siu-Ming Yiu,et al.  Predicting combinative drug pairs via multiple classifier system with positive samples only , 2019, Comput. Methods Programs Biomed..

[11]  Jae Yong Ryu,et al.  Deep learning improves prediction of drug–drug and drug–food interactions , 2018, Proceedings of the National Academy of Sciences.

[12]  Jian-Yu Shi,et al.  Predicting drug-target interaction for new drugs using enhanced similarity measures and super-target clustering. , 2015, Methods.

[13]  D. Bates,et al.  Systems analysis of adverse drug events. ADE Prevention Study Group. , 1995, JAMA.

[14]  Jure Leskovec,et al.  Predicting positive and negative links in online social networks , 2010, WWW '10.

[15]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[16]  V. Traag,et al.  Community detection in networks with positive and negative links. , 2008, Physical review. E, Statistical, nonlinear, and soft matter physics.

[17]  Inderjit S. Dhillon,et al.  Weighted Graph Cuts without Eigenvectors A Multilevel Approach , 2007, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[18]  L. Wienkers,et al.  Predicting in vivo drug interactions from in vitro drug discovery data , 2005, Nature Reviews Drug Discovery.

[19]  Rita Businaro,et al.  Why We Need an Efficient and Careful Pharmacovigilance , 2013 .

[20]  Yanli Wang,et al.  A new chemoinformatics approach with improved strategies for effective predictions of potential drugs , 2018, Journal of Cheminformatics.

[21]  Siu-Ming Yiu,et al.  TMFUF: a triple matrix factorization-based unified framework for predicting comprehensive drug-drug interactions of new drugs , 2018, BMC Bioinformatics.

[22]  Yasen Jiao,et al.  Performance measures in evaluating machine learning based bioinformatics predictors for classifications , 2016, Quantitative Biology.

[23]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[24]  H. Sebastian Seung,et al.  Algorithms for Non-negative Matrix Factorization , 2000, NIPS.

[25]  Peter M. A. Sloot,et al.  A novel feature-based approach to extract drug-drug interactions from biomedical text , 2014, Bioinform..

[26]  D. Back,et al.  Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. , 2015, Gastroenterology.

[27]  C. Altafini,et al.  Computing global structural balance in large-scale signed social networks , 2011, Proceedings of the National Academy of Sciences.

[28]  Xu Han,et al.  Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions , 2012, PLoS Comput. Biol..

[29]  Jitendra Malik,et al.  Normalized cuts and image segmentation , 1997, Proceedings of IEEE Computer Society Conference on Computer Vision and Pattern Recognition.

[30]  Siu-Ming Yiu,et al.  Predicting and understanding comprehensive drug-drug interactions via semi-nonnegative matrix factorization , 2018, BMC Systems Biology.

[31]  Murat Cokol,et al.  Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis , 2017, Science Advances.

[32]  Anna Wolc,et al.  Pharmacokinetic drug‐drug interaction between erlotinib and paracetamol: A potential risk for clinical practice , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  James A. Davis.  Clustering and Structural Balance in Graphs , 1977 .

[34]  John Highton,et al.  Giant cell arteritis treatment failure resulting from probable steroid/antiepileptic drug-drug interaction. , 2017, The New Zealand medical journal.

[35]  George Hripcsak,et al.  Similarity-based modeling in large-scale prediction of drug-drug interactions , 2014, Nature Protocols.

[36]  Ping Zhang,et al.  DDI-CPI, a server that predicts drug–drug interactions through implementing the chemical–protein interactome , 2014, Nucleic Acids Res..

[37]  Ruili Huang,et al.  Comprehensive Characterization of Cytochrome P450 Isozyme Selectivity across Chemical Libraries , 2009, Nature Biotechnology.

[38]  J. Koch-weser,et al.  Serum drug concentrations in clinical perspective. , 1981, Therapeutic drug monitoring.

[39]  Chris H. Q. Ding,et al.  Convex and Semi-Nonnegative Matrix Factorizations , 2010, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[40]  F. Harary.  On the notion of balance of a signed graph. , 1953 .

[41]  Andrew Hill,et al.  How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials , 2009, AIDS.

[42]  L J Lesko,et al.  Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.